Media

PSMA PET/CT Imaging Indications in Prostate Cancer - Neal Shore & Oliver Sartor

Details
Philip Koo, Oliver Sartor, and Neal Shore discuss the revolutionary impact of PSMA PET in the detection and management of prostate cancer. The experts explain the approved indications of PSMA PET agents PSMA 11 and PYLARIFY, emphasizing their transformative role in managing high-risk and intermediate-risk prostate cancer patients. Drs. Shore and Sartor detail how these imaging technologies inform...

NCCN Guidelines On PSMA Molecular Imaging - Tanya Dorff

Details
Alicia Morgans and Tanya Dorff, discuss the updates to the NCCN guidelines since the approval of PSMA PET CT molecular imaging agents. They discuss new guidance based on the FDA-approved indications in the labels for the use of molecular imaging agents for detecting prostate cancer when PSA levels are still relatively low and when PSA levels are rising. Biographies: Tanya B. Dorff, MD., is an asso...

PSMA Imaging - Is Conventional Imaging Obsolete - Steven Rowe

Details
In this Society of Nuclear Medicine and Molecular Imaging- Special Session during the 2021 LUGPA CME presentations, Dr Steven Rowe discusses a number of different scenarios that we might encounter clinically where conventional imaging is clearly being replaced by PSMA based imaging. In the last part of his talk, Dr. Rowe focuses on some future directions where PSMA PET may have some interesting th...

Understanding Physiological PSMA Biodistribution - Jeremie Calais

Details
In this educational initiative, focusing on the knowledge of PSMA PET and PSMA theranostics, Jeremie Calais presents on understanding the physiological PSMA biodistribution and the pathological uptake of the use of PSMA for prostate cancer. Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies: Jeremie Calais, MD, MSc, Director, Clinical Research Pro...

Developing a Theranostics Program, The Nebraska Cancer Specialists Model - Samuel Mehr

Details
In a conversation hosted by Phillip Koo, Sam Mehr outlines the intricacies of establishing a theranostics program within a medical oncology practice. Dr. Mehr discusses the "NCS/Nebraska Cancer Specialists model," which aims to offer targeted nuclear therapy through a patient-centered approach. He emphasizes the importance of a multidisciplinary team, including a program director who serves as the...

Practical Application of 18F-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer: The CONDOR Study - Michael Morris

Details
The CONDOR trial was one of two studies that supported the United States Federal Drug Administration (FDA) submission and subsequent approval of DCFPyL, an 18F radiolabeled PSMA directed PET tracer. The CONDOR trial focused specifically on the rising, the biochemically relapsed patient population, those who had surgery or radiation as their definitive primary therapy, biochemically relapsed, and t...

18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer (CONDOR) Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the Clinical Cancer Research publication on the results from the CONDOR Phase 3, multicenter study. In particular, conventional imaging performs poorly when PSA levels are low, less than 2 ng/mL, and the use of novel PET radiotracers may address this issue and provide more sensitive imaging. CONDOR was a prospective stu...

PYLARIFY®, F 18-labeled PSMA Targeted PET Gains US FDA Approval - Michael Morris

Details
Michael Morris, MD joins Charles Ryan, MD in a discussion on the United States (US) FDA Approval of PYLARIFY®, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent. The F 18 tracer went through two qualifying clinical trials the CONDOR trial and then OSPREY trial. This is the first time a national commercial approval will render PSMA i...

The Impact on Patient Care and Clinical Outcomes Gallium 68 PSMA-11 in Suspected Prostate Cancer Metastasis - Jeremie Calais

Details
On December 1, 2020, the US Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) for use for patients with suspected prostate cancer metastasis in UCLA and UCSF. It is the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. In a follow-up conversation after speaking about the approv...

68Ga-PSMA-11 PET approved in Biochemical Recurrent Prostate Cancer - Jeremie Calais

Details
Jeremie Calais, MD, MSc, joins Phillip Koo, MD, FACS, to discuss the approval of Gallium 68 PSMA-11, the first agent for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. The safety and efficacy of Ga 68 PSMA-11 were evaluated in two prospective clinical trials, which lead to the United States Federal Drug Administ...